Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Guanfacine, Atc N06ba21 For The Period 01.01.2026 To 31.12.2027 (plus Extension Option 1x12 Months) 2026-06-09
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-09
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-09
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Buserelin, Atc L02ae01 For The Period 01.01.2026 To 31.12.2027 2026-06-09
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-09
Germany The Subject Of This Publication Is The Conclusion Of Non-exclusive Agreements For Various Contrast Medium Active Ingredients/active Ingredient Combinations Within The Framework Of A Cross-active Ingredient Open-house Procedure, Which Are Prescribed And Di 2026-06-09
Germany Pharmaceutical Contracts With Option To Join 2026-06-09
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Paliperidone (exclusively 3-month Depot), Atc N05ax13 For The Period 01.01.2026 To 31.12.2027 2026-06-09
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Paragraph 8 Sgb V For The Active Ingredient Lebrikizumab, Atc D11ah10 For The Period 01.01.2026 To 31.12.2027 2026-06-09
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Pazopanib, Atc L01ex03 For The Period 01.01.2026 To 31.12.2027 (plus Extension Option 1x12 Months) 2026-06-09
Whats app